Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

By J. Lau, P. Bloch, L. Schäffer, I. Pettersson, J. Spetzler, Jacob Kofoed, K. Madsen, L. Knudsen, J. McGuire, D. B. Steensgaard and 7 more. Journal of Medicinal Chemistry, 2015

939 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/594349790d0e9a09f8b5843f2782af9cfaaa7bf4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. M. Nauck
2. D. J. Drucker
3. L. Knudsen
4. F. Reimann
5. F. Gribble
6. T. Wadden
7. Ralph DeFronzo
8. J. Meier

In Molecular Biology

1. M. Nauck
2. Jose M. Duarte
3. Hanni Willenbrock
4. Stephen K. Burley
5. Christine Zardecki
6. D. J. Drucker
7. David S. Goodsell
8. John D. Westbrook

In Surgery

1. M. Nauck
2. D. J. Drucker
3. F. Reimann
4. L. Knudsen
5. F. Gribble
6. T. Wadden
7. Ralph DeFronzo
8. J. Meier

Citations in the corpus

• Semaglutide lowers body weight in rodents via distributed neural pathways. (2020, background): “12 hours) and full dipeptidyl peptidase-4 stability (2).”
• LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (2018, methodology): “Preclinical methodology GIP, GLP-1, LY3298176 (C225H348N48O68), semaglutide [39], a longacting GIPR agonist (LA-GIPRA), and [d-Ala(2)]GIP [40] were synthesized at Eli Lilly and Company using traditional peptide chemistry methods and solubilised in PBS, with the exception of [d-Ala(2)]GIP which was f”
• RCSB Protein Data Bank: Enabling biomedical research and drug discovery (2019, background): “GLP1-R 37 is the target of six oligopeptide agonists (exenatide [PDB 3c59, 3c9t], 38 liraglutide [4apd], 39 lixisenatide, albiglutide, dulaglutide, and semaglutide [4zgm] 40 ) approved by the US FDA for treatment of type II diabetes mellitus.”
• Glucagon-like peptide 1 (GLP-1) (2019, background): “Additionally, the palmitic (C16:0) fatty monoacid in liraglutide is exchanged to dicarboxylic-stearic acid (C18:0), and the link to this diacid-based fatty acid is extended relative to that in liraglutide with a synthetic spacer repeat [896].”
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. (2022, background): “Semaglutide’s half-life is 165 hours, resulting from an amino acid replacement (preventing dipeptidyl peptidase 4 degradation) and a C18 fatty diacid addition.(7,8) In a phase 2 trial, once-daily subcutaneous semaglutide, 0.”
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “35,104,116 On August 22, 2022, Novo Nordisk announced the primary results of the Phase II clinical trial for the dual-action compound CagriSema, which demonstrated effective blood sugar reduction and weight loss.”